{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:06:13Z","timestamp":1792119973056,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The histone methyltransferase EZH2 has an essential role in the development of follicular lymphoma (FL). Recurrent gain-of-function mutations in\n                    <jats:italic>EZH2<\/jats:italic>\n                    have been described in 25% of FL patients and induce aberrant methylation of histone H3 lysine 27 (H3K27). We evaluated the role of\n                    <jats:italic>EZH2<\/jats:italic>\n                    genomic gains in FL biology. Using RNA sequencing, Sanger sequencing and SNP-arrays, the mutation status, copy-number and gene-expression profiles of\n                    <jats:italic>EZH2<\/jats:italic>\n                    were assessed in a cohort of 159 FL patients from the PRIMA trial. Immunohistochemical (IHC) EZH2 expression (\n                    <jats:italic>n<\/jats:italic>\n                    =55) and H3K27 methylation (\n                    <jats:italic>n<\/jats:italic>\n                    =63) profiles were also evaluated. In total, 37% of patients (59\/159) harbored an alteration in the\n                    <jats:italic>EZH2<\/jats:italic>\n                    gene (mutation\n                    <jats:italic>n<\/jats:italic>\n                    =46, gain\n                    <jats:italic>n<\/jats:italic>\n                    =23). Both types of alterations were associated with highly similar transcriptional changes, with increased proliferation programs. An H3K27me3\/me2 IHC score fully distinguished mutated from wild-type samples, showing its applicability as surrogate for\n                    <jats:italic>EZH2<\/jats:italic>\n                    mutation analysis. However, this score did not predict the presence of gains at the\n                    <jats:italic>EZH2<\/jats:italic>\n                    locus. The presence of an\n                    <jats:italic>EZH2<\/jats:italic>\n                    genetic alteration was an independent factor associated with a longer progression-free survival (hazard ratio 0.58, 95% confidence interval 0.36\u20130.93,\n                    <jats:italic>P<\/jats:italic>\n                    =0.025). We propose that the copy-number status of\n                    <jats:italic>EZH2<\/jats:italic>\n                    should also be considered when evaluating patient stratification and selecting patients for EZH2 inhibitor-targeted therapies.\n                  <\/jats:p>","DOI":"10.1038\/bcj.2017.32","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T09:21:35Z","timestamp":1492766495000},"page":"e555-e555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["EZH2 alterations in follicular lymphoma: biological and clinical correlations"],"prefix":"10.1038","volume":"7","author":[{"given":"S","family":"Huet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Xerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Tesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mareschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Taix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Mescam-Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Sohier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Carr\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lazarovici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Boyault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Viari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"BFbcj201732_CR1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008."},{"key":"BFbcj201732_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","volume":"98","author":"E Bachy","year":"2013","unstructured":"Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K et al. Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 2013; 98: 1107\u20131114.","journal-title":"Haematologica"},{"key":"BFbcj201732_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181\u2013185.","journal-title":"Nat Genet"},{"key":"BFbcj201732_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature09730","volume":"471","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189\u2013195.","journal-title":"Nature"},{"key":"BFbcj201732_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111\u20131122.","journal-title":"Lancet Oncol"},{"key":"BFbcj201732_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vir\u00e9","year":"2006","unstructured":"Vir\u00e9 E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871\u2013874.","journal-title":"Nature"},{"key":"BFbcj201732_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039\u20131043.","journal-title":"Science"},{"key":"BFbcj201732_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D . The polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343\u2013349.","journal-title":"Nature"},{"key":"BFbcj201732_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","volume":"46","author":"J Okosun","year":"2014","unstructured":"Okosun J, B\u00f6d\u00f6r C, Wang J, Araf S, Yang C-Y, Pan C et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014; 46: 176\u2013181.","journal-title":"Nat Genet"},{"key":"BFbcj201732_CR10","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","volume":"122","author":"C B\u00f6d\u00f6r","year":"2013","unstructured":"B\u00f6d\u00f6r C, Grossmann V, Popov N, Okosun J, O\u2019Riain C, Tan K et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013; 122: 3165\u20133168.","journal-title":"Blood"},{"key":"BFbcj201732_CR11","doi-asserted-by":"publisher","first-page":"20980","DOI":"10.1073\/pnas.1012525107","volume":"107","author":"CJ Sneeringer","year":"2010","unstructured":"Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010; 107: 20980\u201320985.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201732_CR12","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","volume":"117","author":"DB Yap","year":"2011","unstructured":"Yap DB, Chu J, Berg T, Schapira M, Cheng S-WG, Moradian A et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117: 2451\u20132459.","journal-title":"Blood"},{"key":"BFbcj201732_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108\u2013112.","journal-title":"Nature"},{"key":"BFbcj201732_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W B\u00e9guelin","year":"2013","unstructured":"B\u00e9guelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677\u2013692.","journal-title":"Cancer Cell"},{"key":"BFbcj201732_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/nm.4092","volume":"22","author":"GP Souroullas","year":"2016","unstructured":"Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu J-Y, Paulk J et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med 2016; 22: 632\u2013640.","journal-title":"Nat Med"},{"key":"BFbcj201732_CR16","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1172\/JCI70626","volume":"123","author":"M Caganova","year":"2013","unstructured":"Caganova M, Carrisi C, Varano G, Mainoldi F, Zanardi F, Germain P-L et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest 2013; 123: 5009\u20135022.","journal-title":"J Clin Invest"},{"key":"BFbcj201732_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","volume":"13","author":"SK Knutson","year":"2014","unstructured":"Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang K-C, Xiao Y et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014; 13: 842\u2013854.","journal-title":"Mol Cancer Ther"},{"key":"BFbcj201732_CR18","doi-asserted-by":"publisher","first-page":"21360","DOI":"10.1073\/pnas.1210371110","volume":"109","author":"W Qi","year":"2012","unstructured":"Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012; 109: 21360\u201321365.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201732_CR19","doi-asserted-by":"publisher","first-page":"16712","DOI":"10.18632\/oncotarget.3154","volume":"6","author":"S Dubois","year":"2015","unstructured":"Dubois S, Mareschal S, Picquenot J-M, Viailly P-J, Bohers E, Cornic M et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget 2015; 6: 16712\u201316724.","journal-title":"Oncotarget"},{"key":"BFbcj201732_CR20","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.3109\/10428194.2015.1006220","volume":"56","author":"Z Zhou","year":"2015","unstructured":"Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter JN et al. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma 2015; 56: 2895\u20132901.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201732_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/gcc.1103","volume":"30","author":"DE Horsman","year":"2001","unstructured":"Horsman DE, Connors JM, Pantzar T, Gascoyne RD . Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 2001; 30: 375\u2013382.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFbcj201732_CR22","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","volume":"123","author":"A Bouska","year":"2014","unstructured":"Bouska A, McKeithan TW, Deffenbacher KE, Lachel C, Wright GW, Iqbal J et al. Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 2014; 123: 1681\u20131690.","journal-title":"Blood"},{"key":"BFbcj201732_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42\u201351.","journal-title":"Lancet"},{"key":"BFbcj201732_CR24","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","volume":"14","author":"D Kim","year":"2013","unstructured":"Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL . TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013; 14: R36.","journal-title":"Genome Biol"},{"key":"BFbcj201732_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297\u20131303.","journal-title":"Genome Res"},{"key":"BFbcj201732_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W . HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 2015; 31: 166\u2013169.","journal-title":"Bioinformatics"},{"key":"BFbcj201732_CR27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.","journal-title":"Genome Biol"},{"key":"BFbcj201732_CR28","doi-asserted-by":"publisher","first-page":"R128","DOI":"10.1186\/gb-2009-10-11-r128","volume":"10","author":"T Popova","year":"2009","unstructured":"Popova T, Mani\u00e9 E, Stoppa-Lyonnet D, Rigaill G, Barillot E, Stern MH . Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 2009; 10: R128.","journal-title":"Genome Biol"},{"key":"BFbcj201732_CR29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289\u2013300.","journal-title":"J R Stat Soc Ser B"},{"key":"BFbcj201732_CR30","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545\u201315550.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201732_CR31","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 2015; 33: 2516\u20132522.","journal-title":"J Clin Oncol"},{"key":"BFbcj201732_CR32","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesqui\u00e8res H, Ansell SM, Nowakowski GS, Thompson CA et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 2016; 91: 1096\u20131101.","journal-title":"Am J Hematol"},{"key":"BFbcj201732_CR33","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1182\/blood-2010-04-280149","volume":"116","author":"I Velichutina","year":"2010","unstructured":"Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247\u20135255.","journal-title":"Blood"},{"key":"BFbcj201732_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1182\/blood-2015-12-682591","volume":"128","author":"A Louissaint","year":"2016","unstructured":"Louissaint A, Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood 2016; 128: 1093\u20131100.","journal-title":"Blood"},{"key":"BFbcj201732_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1182\/blood-2016-03-703819","volume":"128","author":"J Schmidt","year":"2016","unstructured":"Schmidt J, Gong S, Marafioti T, Mankel B, Gonzalez-Farre B, Balagu\u00e9 O et al. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood 2016; 128: 1101\u20131111.","journal-title":"Blood"},{"key":"BFbcj201732_CR36","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 2016; 128: 1112\u20131120.","journal-title":"Blood"},{"key":"BFbcj201732_CR37","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood-2014-02-553693","volume":"123","author":"C Sarkozy","year":"2014","unstructured":"Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S et al. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood 2014; 123: 2740\u20132742.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201732","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T14:21:07Z","timestamp":1719152467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"alternative-id":["BFbcj201732"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.32","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]},"assertion":[{"value":"8 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GS has received research support and honoraria for advisory board meetings and symposia from Roche\/Genentech. Remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}